- Home
- KWR vs TVTX Comparison
KWR vs TVTX Comparison
Compare KWR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWR
- TVTX
- Stock Information
- Founded
- KWR 1918
- TVTX 2008
- Country
- KWR United States
- TVTX United States
- Employees
- KWR N/A
- TVTX N/A
- Industry
- KWR Major Chemicals
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- KWR Industrials
- TVTX Health Care
- Exchange
- KWR Nasdaq
- TVTX Nasdaq
- Market Cap
- KWR 2.0B
- TVTX 1.7B
- IPO Year
- KWR 1985
- TVTX N/A
- Fundamental
- Price
- KWR $109.67
- TVTX $15.32
- Analyst Decision
- KWR Strong Buy
- TVTX Strong Buy
- Analyst Count
- KWR 4
- TVTX 14
- Target Price
- KWR $157.75
- TVTX $33.31
- AVG Volume (30 Days)
- KWR 151.3K
- TVTX 1.8M
- Earning Date
- KWR 08-04-2025
- TVTX 07-31-2025
- Dividend Yield
- KWR 1.77%
- TVTX N/A
- EPS Growth
- KWR N/A
- TVTX N/A
- EPS
- KWR 5.29
- TVTX N/A
- Revenue
- KWR $1,812,841,000.00
- TVTX $273,533,000.00
- Revenue This Year
- KWR $1.16
- TVTX $74.73
- Revenue Next Year
- KWR $5.05
- TVTX $44.19
- P/E Ratio
- KWR $20.73
- TVTX N/A
- Revenue Growth
- KWR N/A
- TVTX 75.65
- 52 Week Low
- KWR $95.91
- TVTX $6.80
- 52 Week High
- KWR $193.74
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- KWR 53.82
- TVTX 40.05
- Support Level
- KWR $105.50
- TVTX $14.50
- Resistance Level
- KWR $108.84
- TVTX $15.64
- Average True Range (ATR)
- KWR 3.18
- TVTX 0.76
- MACD
- KWR 0.37
- TVTX -0.18
- Stochastic Oscillator
- KWR 70.66
- TVTX 24.55
About KWR Quaker Houghton
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.